6340-55-2

Basic information

• Product Name: 2,6-DIMETHOXY-4-METHYLQUINOLINE
• Synonyms: 2,6-DIMETHOXY-4-METHYLQUINOLINE;2-Chloro-6-methoxylepidine;Quinoline, 2-chloro-6-Methoxy-4-Methyl-
• CAS NO: 6340-55-2
• Molecular Formula: C₁₁H₁₀ClNO
• Molecular Weight: 207.66
• Mol File: 6340-55-2.mol

Chemical Properties

• Appearance: /
• Density: 1.287g/cm³
• Refractive Index: 1.621
• CAS DataBase Reference: 2,6-DIMETHOXY-4-METHYLQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIMETHOXY-4-METHYLQUINOLINE(6340-55-2)
• EPA Substance Registry System: 2,6-DIMETHOXY-4-METHYLQUINOLINE(6340-55-2)

Safety Data

• Hazardous Substances Data: 6340-55-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-DIMETHOXY-4-METHYLQUINOLINE is used as an intermediate in the synthesis of Tafenoquine-d3 Succinate, which is the labelled analog of Tafenoquine (T004760). Tafenoquine is a new 8-aminoquinoline with an enhanced therapeutic index and safety profile compared to primaquine (P733500). It has the potential to become a widely used drug in the prevention and treatment of malaria infections, particularly as resistant strains of Plasmodium species continue to emerge. The development of Tafenoquine and its analogs can lead to more effective and safer treatments for malaria, reducing the global burden of this disease.

InChI:InChI=1/C24H24N2O6/c1-4-7-16-12-15(14-20(21(16)27)32-6-3)13-19-22(28)25-24(30)26(23(19)29)17-8-10-18(11-9-17)31-5-2/h4,8-14,27H,1,5-7H2,2-3H3,(H,25,28,30)/b19-13+

Upstream product

• 5342-23-4 2-hydroxy-4-methyl-6-methoxyquinoline 
• 104-94-9 4-methoxy-aniline 
• 5342-23-4 6-methoxy-4-methyl-2-oxo-1H-quinoline 
• 5437-98-9 4'-methoxyacetoacetanilide 

Downstream Products

• 94960-01-7 4-(6-methoxy-4-methyl-quinolin-2-ylamino)-benzenesulfonamide 
• 52323-10-1 6-methoxy-4-methyl-quinoline-2-thiol 
• 359784-21-7 2-phenoxy-4-methyl-6-methoxyquinoline 
• 71509-00-7 2-(3',5'-dimethylpyrazol-1'-yl)-4-methyl-6-methoxyquinoline 
• 258521-45-8 6-methoxy-4-methyl-2-(4-methyl-2-nitroanilino)quinoline 
• 258521-46-9 6-methoxy-2-(4-methoxy-2-nitroanilino)-4-methylquinoline 
• 359784-25-1 2-phenoxy-6-methoxyquinoline-4-carbaldehyde 
• 359784-26-2 2-phenoxy-6-methoxyquinoline-4-carboxylic acid 
• 359784-27-3 2-phenoxy-6-methoxyquinoline-4-carbonyl chloride 
• 359784-28-4 4-(diazomethylene)carbonyl-2-phenoxy-6-methoxyquinoline 
• 359784-29-5 2-(6-methoxy-2-phenoxy-quinolin-4-yl)-acetamide 

Relevant articles and documents

Compounds having anticonvulsion activity, preparing methods thereof and applications of the compounds

The invention provides 7-substituted-5-methyl-1,2,4-triazolo[4,3-a] quinoline and 7-substituted-5-ethoxy-[1,2,4]-triazolo[4,3-a] quinoline compounds having anticonvulsion activity, preparing methods thereof and applications of the compounds in the field of preparing anticonvulsion medicines.

Process for the preparation of anti-malarial drugs

The invention relates to novel intermediates and processes for the preparation of quinoline compounds useful as anti-malarial drugs and novel intermediates useful in the process. A process for the preparation of a compound of formula (I) in which R1is C1-6alkyl; R2and R3are independently hydrogen, halogen, trifluoromethyl or C1-6alkoxy; R4is C1-6alkyl; R5is hydrogen or C1-6alkyl; and R6or amino which comprises reacting a compound of formula (II) in which R1, R4and R5are as defined in formula (I) and X is a leading group with a compound of formula (III).

Quinoline-4-acetamides as sPLA2 inhibitors

Quinoline-4-acetamides were designed as potential phospholipase A2 inhibitors by structural based method and synthesized. The chemical structures of the obtained compounds were confirmed by elemental analyses, 1H NMR and MS. Preliminary bioassay study shows that quinoline-4-acetamides display certain inhibition to sPLA2.

Pyridine and related aza heterocycle derivatives as cardiovascular agents

Novel pharmaceutical compounds and compositions having nitrogen containing ring systems which may be represented by the following structural formula: wherein R1 or R3 is a moiety of the formula: wherein R6 is selected from either hydrogen or acetyl; R7 is selected from 2, 3 or 4-pyridyl or 1-imidazolyl and Q is -(CH2)n, where n is an integer from 1 to 5 and R1 and R2, R2 and R3, R3 and R4 or R4 and R5 taken together may be -CH=CH-CH=CH-. The compounds and compositions are useful as inhibitors of thromboxane synthetase and in the treatment of hypertension and arrythmia in mammals.